# Harbour BioMed Partner Spruce Biosciences Separates CRHX-101 Program Into Adrenyx Biosciences

> Spruce Biosciences separated CRHX-101 into Adrenyx Biosciences, backed by a $5 million convertible note and a private placement of up to $50 million.

- Published: 2026-11-18T00:47:53+00:00
- Section: Divestitures
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-18/harbour-biomed-spruce-adrenyx-crhx-101
- Source: [Stock Titan](https://www.stocktitan.net/news/SPRB/harbour-bio-med-s-partner-spruce-biosciences-separates-crhx-101-n9gd52s411ot.html)

## Key takeaways

- Spruce Biosciences separated its CRHX-101 program into Adrenyx Biosciences, a wholly-owned subsidiary expected to list on Nasdaq in the first half of 2027.
- Adrenyx secured an initial $5 million under a secured convertible note purchase arrangement, with potential to issue up to $10 million in aggregate principal.
- A private placement of Adrenyx equity to institutional investors is expected alongside the planned distribution, with up to $50 million funded by the convertible notes investor.
- CRHX-101 originated from HBM Alpha Therapeutics, which in January 2025 licensed rights outside Greater China to Spruce for up to $395 million in milestones and royalties.

Harbour BioMed's partner Spruce Biosciences has separated its CRHX-101 program into Adrenyx Biosciences, a newly established, wholly-owned subsidiary focused on endocrinology, with Adrenyx expected to list on Nasdaq in the first half of 2027. [Stock Titan](https://www.stocktitan.net/news/SPRB/harbour-bio-med-s-partner-spruce-biosciences-separates-crhx-101-n9gd52s411ot.html) published the announcement on November 17, 2026. Harbour BioMed is a global biopharmaceutical company developing novel antibody therapeutics in immunology, oncology and other areas. [Spruce Biosciences](https://akta.pro/company-profiles/0000rrd/spruce-biosciences) is the Nasdaq-listed partner that held exclusive rights to develop and commercialize CRHX-101 outside Greater China.

## How the Adrenyx Separation Is Structured

CRHX-101, formerly SPR-202 and HBM9013, is a monoclonal antibody designed to selectively neutralize corticotropin-releasing hormone, an upstream driver of adrenal androgen excess in classic congenital adrenal hyperplasia. The program is being developed with the potential to achieve durable upstream disease control and reduce patients' reliance on chronic high-dose glucocorticoid therapy.

Upon completion of the planned pro rata distribution of Adrenyx common stock to Spruce shareholders, Harbour BioMed expects to hold equity interests in both Spruce and Adrenyx. Adrenyx has secured an initial $5 million under a secured convertible note purchase arrangement, with the potential to issue up to $10 million in aggregate principal amount. A private placement of Adrenyx equity securities to institutional investors is expected to be completed in connection with the planned distribution, with up to $50 million funded by the convertible notes investor, inclusive of the notes funding.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, said: "We are pleased to see the continued advancement of CRHX-101 through a dedicated corporate structure. The establishment of Adrenyx reflects a focused approach to advancing CRHX-101 and supporting its next stage of development."

CRHX-101 originated from HBM Alpha Therapeutics, a biotechnology company incubated by Harbour BioMed. In January 2025, HBMAT entered into a collaboration and license agreement with Spruce granting exclusive rights outside Greater China, including mainland China, Hong Kong, Macau and Taiwan. Under the agreement, HBMAT is eligible to receive up to $395 million, including upfront, development, regulatory and commercial milestone payments, as well as tiered royalties on future net product sales. HBMAT was also granted a warrant to receive minority interest in the partner, and in January 2026 Harbour BioMed announced that its wholly-owned subsidiary had exercised the warrants.

## Harbour BioMed's Approvals and Appointments Before the Spinoff

On October 23, 2026, China's NMPA approved batoclimab subcutaneous injection for generalized myasthenia gravis in adult AChR-Ab positive patients, based on a Phase 3 trial at 27 centers, PR Newswire reported. The drug achieved sustained MG-ADL improvement in 58.2% of patients versus 31.3% on placebo (P=0.001).

On November 5, 2026, Harbour BioMed appointed Vivian Feng as Senior Vice President, Head of External Collaboration, based in Shanghai, to lead external collaboration strategy, business development and licensing across the HBM Group, PR Newswire reported. On November 17, 2026, the company appointed Dr. Sanjay Keswani as Scientific Advisor in Neuroscience, citing his more than 25 years of experience, TradingView reported.

## Adrenyx's Near-Term Steps and Planned Listing

Adrenyx's near-term priorities include completion of IND-enabling nonclinical and chemistry, manufacturing and controls activities, the filing of an Investigational New Drug application for CRHX-101 with the U.S. Food and Drug Administration, and initiation of a clinical program thereafter. The planned pro rata distribution of Adrenyx common stock to Spruce shareholders and the Nasdaq listing are expected in the first half of 2027.

## Companies in this story

- Harbour Biomed · website: https://www.harbourbiomed.com
- [Spruce Biosciences company profile](https://akta.pro/company-profiles/0000rrd/spruce-biosciences) · website: https://www.sprucebiosciences.com

---
News for Agent · https://newsforagent.com/llms.txt
